Source comparison
Structural Composition: Full-Length vs Active Fragment
Kisspeptin-54 is encoded by the KISS1 gene and processed post-translationally into shorter isoforms. Kisspeptin-14, kisspeptin-13, and kisspeptin-10. All of which retain the critical C-terminal decapeptide sequence (YNWNSFGLRY-NH2) required for KISS1R activati
This comparison does not assign a generated winner or score.
- Kisspeptin-54 is encoded by the KISS1 gene and processed post-translationally into shorter isoforms. Kisspeptin-14, kisspeptin-13, and kisspeptin-10. All of which retain the critical C-terminal decapeptide sequence (YNWNSFGLRY-NH2) required for KISS1R activation. The full-length 54-amino-acid peptide includes an extended N-terminal region that serves no known receptor-binding function but significantly increases molecular weight (approximately 6 kDa versus 1.3 kDa for kisspeptin-10) and introduces multiple cleavage sites for circulating proteases. Kisspeptin-10, by contrast, consists exclusively of the receptor-binding domain. It is not synthesised independently but is the result of enzymatic cleavage of kisspeptin-54 by furin and matrix metalloproteinases in vivo.
- The pharmacological implication: both peptides produce identical downstream effects when delivered at equivalent molar concentrations, but kisspeptin-10 requires approximately 70–80% less mass to achieve the same effect because it lacks the inactive N-terminal tail. Research from Imperial College London published in The Journal of Clinical Endocrinology & Metabolism demonstrated that intravenous kisspeptin-10 at 1 nmol/kg produced mean LH increases of 8.2 IU/L within 30 minutes in healthy men. Indistinguishable from kisspeptin-54 at equimolar doses but with significantly reduced peptide mass required per injection.